Xencor

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Xencor and other ETFs, options, and stocks.

About XNCR

Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions.

CEO

Bassil I. Dahiyat

CEOBassil I. Dahiyat

Employees

260

Employees260

Headquarters

Pasadena, California

HeadquartersPasadena, California

Founded

1997

Founded1997

Employees

260

Employees260

XNCR Key Statistics

Market cap

1.88B

Market cap1.88B

Price-Earnings ratio

-10.18

Price-Earnings ratio-10.18

Dividend yield

—

Dividend yield—

Average volume

1.09M

Average volume1.09M

High today

$23.10

High today$23.10

Low today

$21.90

Low today$21.90

Open price

$22.13

Open price$22.13

Volume

268.20K

Volume268.20K

52 Week high

$23.10

52 Week high$23.10

52 Week low

$7.02

52 Week low$7.02

Stock Snapshot

With a market cap of 1.88B, Xencor(XNCR) trades at $22.77. The stock has a price-to-earnings ratio of -10.18.

During the trading session on 2026-08-12, Xencor(XNCR) shares reached a daily high of $23.10 and a low of $21.90. At a current price of $22.77, the stock is +4.0% higher than the low and still -1.4% under the high.

Trading volume for Xencor(XNCR) stock has reached 268.2K, versus its average volume of 1.09M.

The stock's 52-week range extends from a low of $7.02 to a high of $23.10.

XNCR News

Investing.com 1d

Xencor stock hits 52-week high at 21.99 USD - Investing.com

...

Simply Wall St 1d

Xencor Could Be 24% Below Fair Value On Narrower Quarterly Loss

Advertisement Xencor earnings event and what it might mean for the stock Xencor (XNCR) shares are in focus after second quarter results on 5 August 2026 showe...

Simply Wall St 6d

Does Xencor’s Mixed 2026 Loss Trend Reshape the Investment Narrative Around XNCR’s R&D Priorities?

Xencor, Inc. has reported its second-quarter and half-year 2026 results, with quarterly net loss narrowing to US$21.73 million and basic loss per share from con...

Analyst ratings

86%

of 14 ratings

Buy

85.7%

Hold

14.3%

Sell

More XNCR News

TipRanks 6d

Analyst John Newman Reiterates Buy on Xencor, Citing Late-Stage XmAb Pipeline, Non-Dilutive Cash Inflows and Royalties, and Sets $38 Price Target

Xencor, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst John Newman from Canaccord Genuity maintained a Buy rating on t...

TipRanks 6d

Xencor price target raised to $20 from $19 at RBC Capital

RBC Capital raised the firm’s price target on Xencor (XNCR) to $20 from $19 and keeps an Outperform rating on the shares. Unlock powerful investing tools with...

People also own

Based on the portfolios of people who own XNCR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.